TY - JOUR
T1 - RNA interference-based therapy and its delivery systems
AU - Chen, Xiuhui
AU - Mangala, Lingegowda S.
AU - Rodriguez-Aguayo, Cristian
AU - Kong, Xianchao
AU - Lopez-Berestein, Gabriel
AU - Sood, Anil K.
N1 - Publisher Copyright:
© 2017, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - RNA interference (RNAi) is considered a highly specific approach for gene silencing and holds tremendous potential for treatment of various pathologic conditions such as cardiovascular diseases, viral infections, and cancer. Although gene silencing approaches such as RNAi are widely used in preclinical models, the clinical application of RNAi is challenging primarily because of the difficulty in achieving successful systemic delivery. Effective delivery systems are essential to enable the full therapeutic potential of RNAi. An ideal nanocarrier not only addresses the challenges of delivering naked siRNA/miRNA, including its chemically unstable features, extracellular and intracellular barriers, and innate immune stimulation, but also offers “smart” targeted delivery. Over the past decade, great efforts have been undertaken to develop RNAi delivery systems that overcome these obstacles. This review presents an update on current progress in the therapeutic application of RNAi with a focus on cancer therapy and strategies for optimizing delivery systems, such as lipid-based nanoparticles.
AB - RNA interference (RNAi) is considered a highly specific approach for gene silencing and holds tremendous potential for treatment of various pathologic conditions such as cardiovascular diseases, viral infections, and cancer. Although gene silencing approaches such as RNAi are widely used in preclinical models, the clinical application of RNAi is challenging primarily because of the difficulty in achieving successful systemic delivery. Effective delivery systems are essential to enable the full therapeutic potential of RNAi. An ideal nanocarrier not only addresses the challenges of delivering naked siRNA/miRNA, including its chemically unstable features, extracellular and intracellular barriers, and innate immune stimulation, but also offers “smart” targeted delivery. Over the past decade, great efforts have been undertaken to develop RNAi delivery systems that overcome these obstacles. This review presents an update on current progress in the therapeutic application of RNAi with a focus on cancer therapy and strategies for optimizing delivery systems, such as lipid-based nanoparticles.
KW - Cancer therapy
KW - Delivery systems
KW - Nanoparticles
KW - RNA interference
UR - http://www.scopus.com/inward/record.url?scp=85038123518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038123518&partnerID=8YFLogxK
U2 - 10.1007/s10555-017-9717-6
DO - 10.1007/s10555-017-9717-6
M3 - Article
C2 - 29243000
AN - SCOPUS:85038123518
SN - 0167-7659
VL - 37
SP - 107
EP - 124
JO - Cancer and Metastasis Reviews
JF - Cancer and Metastasis Reviews
IS - 1
ER -